Henrike E Karim-Kos1, Monika Hackl2, Georg Mann3, Christian Urban4, Adelheid Woehrer5, Irene Slavc6, Ruth Ladenstein7. 1. Austrian National Cancer Registry, Directorate Social Statistics, Statistics Austria, Guglgasse 13, 1110 Vienna, Austria. Electronic address: henrike.kos@statistik.gv.at. 2. Austrian National Cancer Registry, Directorate Social Statistics, Statistics Austria, Guglgasse 13, 1110 Vienna, Austria. Electronic address: monika.hackl@statistik.gv.at. 3. The Children Cancer Research Institute, St. Anna Children's Hospital, Kinderspitalgasse 6, 1090 Vienna, Austria. Electronic address: georg.mann@stanna.at. 4. Department of Paediatrics and Adolescent Medicine, Division of Haemato-Oncology, Medical University of Graz, Auenbruggerplatz 34, 8036 Graz, Austria. Electronic address: christian.urban@medunigraz.at. 5. Institute of Neurology, Medical University of Vienna, Währinger Gürtel 18-20, 1090 Vienna, Austria. Electronic address: adelheid.woehrer@meduniwien.ac.at. 6. Department of Pediatrics and Adolescent Medicine, Medical University of Vienna, Währinger Gürtel 18-20, 1090 Vienna, Austria. Electronic address: irene.slavc@meduniwien.ac.at. 7. The Children Cancer Research Institute, St. Anna Children's Hospital, Kinderspitalgasse 6, 1090 Vienna, Austria. Electronic address: ruth.ladenstein@ccri.at.
Abstract
BACKGROUND: This is the first study on trends in cancer incidence, survival and mortality for children and adolescents in Austria. The aim was to assess to what extent progress against childhood and adolescent cancer has been made in Austria since the 1990s and to complement the childhood and adolescent cancer trends for Central Europe. METHODS: All malignant neoplasms and non-malignant tumours of the Central Nervous System (CNS) in patients aged less than 20 years and diagnosed between 1994 and 2011 (N=5425) were derived from the Austrian National Cancer Registry (ANCR). Incidence and mortality trends were evaluated by the average annual percentage change (AAPC). Observed survival rates were calculated based on follow-up until December 31st 2013. RESULTS: Childhood cancer remained stable with 182 cases per million in 2011, but rose among girls by 1.4% (95% CI: .1, 3.6) annually due to an increase of non-malignant CNS tumours and Non-Hodgkin lymphoma. Adolescent cancer rose by 1.5% (95% CI: .4, 2.6) annually, from 182 cases per million in 1994-269 in 2011, especially leukaemia, CNS tumours (including non-malignant types) and epithelial tumours. Five-year survival improved by 5-7% reaching 86% for both groups (p<.05). Mortality declined by -2.4% (95% CI: -3.7, -1.2) and -2.0% (95% CI: -4.6, .5), respectively, especially for childhood leukaemia. CONCLUSION: Progress is demonstrated by improved survival and declined mortality most likely related to improved diagnostic techniques, more effective therapeutic regimes, supportive care and a central advisory function of experts in the Austrian paediatric oncology.
BACKGROUND: This is the first study on trends in cancer incidence, survival and mortality for children and adolescents in Austria. The aim was to assess to what extent progress against childhood and adolescent cancer has been made in Austria since the 1990s and to complement the childhood and adolescent cancer trends for Central Europe. METHODS: All malignant neoplasms and non-malignant tumours of the Central Nervous System (CNS) in patients aged less than 20 years and diagnosed between 1994 and 2011 (N=5425) were derived from the Austrian National Cancer Registry (ANCR). Incidence and mortality trends were evaluated by the average annual percentage change (AAPC). Observed survival rates were calculated based on follow-up until December 31st 2013. RESULTS: Childhood cancer remained stable with 182 cases per million in 2011, but rose among girls by 1.4% (95% CI: .1, 3.6) annually due to an increase of non-malignant CNS tumours and Non-Hodgkin lymphoma. Adolescent cancer rose by 1.5% (95% CI: .4, 2.6) annually, from 182 cases per million in 1994-269 in 2011, especially leukaemia, CNS tumours (including non-malignant types) and epithelial tumours. Five-year survival improved by 5-7% reaching 86% for both groups (p<.05). Mortality declined by -2.4% (95% CI: -3.7, -1.2) and -2.0% (95% CI: -4.6, .5), respectively, especially for childhood leukaemia. CONCLUSION: Progress is demonstrated by improved survival and declined mortality most likely related to improved diagnostic techniques, more effective therapeutic regimes, supportive care and a central advisory function of experts in the Austrian paediatric oncology.
Authors: R Marcos-Gragera; M Solans; J Galceran; R Fernández-Delgado; A Fernández-Teijeiro; A Mateos; J R Quirós-Garcia; N Fuster-Camarena; V De Castro; M J Sánchez; P Franch; M D Chirlaque; E Ardanaz; C Martos; D Salmerón; R Peris-Bonet Journal: Clin Transl Oncol Date: 2018-04-05 Impact factor: 3.405
Authors: Karwan M-Amen; Omiad S Abdullah; Ahmed M S Amin; Zeki Ali Mohamed; Bestoon Hasan; Mudhir Shekha; Hastyar H Najmuldeen; Fryad Majeed Rahman; Zjwan Housein; Ahmed M Salih; Amin Salih Mohammed; Luqman Rahman Sulaiman; Basak Tahir Barzingi; Dler Mahmood; Hemin Esmael Othman; Dara K Mohammad; Fahmi M Salih; Suad As Khudhur Ali; Trefa S Mohamad; Kazhan Mahmood; Galawezh O Othman; Mukhlis H Aali; Govand Qader; Bashdar M Hussen; Farhang A Awla; Shahab Wahhab Kareem; Fikry A Qadir; Dilan M Taher; Abbas Salihi Journal: Asian Pac J Cancer Prev Date: 2022-02-01
Authors: Travis Kotzur; Roberto Benavides-Garcia; Jennifer Mecklenburg; Jamila R Sanchez; Matthew Reilly; Brian P Hermann Journal: Reprod Biol Endocrinol Date: 2017-01-11 Impact factor: 5.211
Authors: Eva Steliarova-Foucher; Miranda M Fidler; Murielle Colombet; Brigitte Lacour; Peter Kaatsch; Marion Piñeros; Isabelle Soerjomataram; Freddie Bray; Jan Willem Coebergh; Rafael Peris-Bonet; Charles A Stiller Journal: Lancet Oncol Date: 2018-08-08 Impact factor: 41.316
Authors: Ardine M J Reedijk; Eline A M Zijtregtop; Jan Willem W Coebergh; Friederike A G Meyer-Wentrup; Konnie M Hebeda; C Michel Zwaan; Geert O R Janssens; Rob Pieters; Wouter J Plattel; Avinash G Dinmohamed; Josée M Zijlstra; Leontien C M Kremer; Pieternella J Lugtenburg; Auke Beishuizen; Henrike E Karim-Kos Journal: Br J Haematol Date: 2020-02-06 Impact factor: 6.998
Authors: Janet Flores-Lujano; David Aldebarán Duarte-Rodríguez; Elva Jiménez-Hernández; Jorge Alfonso Martín-Trejo; Aldo Allende-López; José Gabriel Peñaloza-González; María Luisa Pérez-Saldivar; Aurora Medina-Sanson; José Refugio Torres-Nava; Karina Anastacia Solís-Labastida; Luz Victoria Flores-Villegas; Rosa Martha Espinosa-Elizondo; Raquel Amador-Sánchez; Martha Margarita Velázquez-Aviña; Laura Elizabeth Merino-Pasaye; Nora Nancy Núñez-Villegas; Ana Itamar González-Ávila; María de Los Ángeles Del Campo-Martínez; Martha Alvarado-Ibarra; Vilma Carolina Bekker-Méndez; Rocío Cárdenas-Cardos; Silvia Jiménez-Morales; Roberto Rivera-Luna; Haydee Rosas-Vargas; Norma C López-Santiago; Angélica Rangel-López; Alfredo Hidalgo-Miranda; Elizabeth Vega; Minerva Mata-Rocha; Omar Alejandro Sepúlveda-Robles; José Arellano-Galindo; Juan Carlos Núñez-Enríquez; Juan Manuel Mejía-Aranguré Journal: Front Public Health Date: 2022-09-14